The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) is a huge mover today! About 110,467 shares traded hands. Intellia Therapeutics Inc (NASDAQ:NTLA) has risen 6.00% since October 8, 2016 and is uptrending. It has outperformed by 4.04% the S&P500.
The move comes after 6 months positive chart setup for the $522.01 million company. It was reported on Nov, 7 by Barchart.com. We have $19.11 PT which if reached, will make NASDAQ:NTLA worth $156.60M more.
Intellia Therapeutics Inc (NASDAQ:NTLA) Ratings Coverage
Out of 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Intellia Therapeutics has been the topic of 5 analyst reports since May 31, 2016 according to StockzIntelligence Inc. Credit Suisse initiated the shares of NTLA in a report on Tuesday, May 31 with “Outperform” rating. The firm has “Outperform” rating given on Tuesday, May 31 by Wedbush. As per Friday, August 5, the company rating was upgraded by Jefferies. The stock has “Outperform” rating given by Leerink Swann on Friday, August 5. Jefferies initiated Intellia Therapeutics Inc (NASDAQ:NTLA) rating on Tuesday, May 31. Jefferies has “Hold” rating and $33 price target.
According to Zacks Investment Research, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”
More news for Intellia Therapeutics Inc (NASDAQ:NTLA) were recently published by: Marketwatch.com, which released: “Virtual Stock Exchange” on April 16, 2016. Globenewswire.com‘s article titled: “Intellia Therapeutics to Present at 2016 Wedbush PacGrow Healthcare Conference” and published on August 10, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.